Movement Alert｜EVEREST MED Falls 5.19% in Regular Trading, mRNA Concept Pullback and Biotech Sector Weakness Weigh on Shares

Market Focus08-31 10:09

On August 31, EVEREST MED fell 5.19% in regular trading, trading at HK$33.0/share, with turnover of HK$108 million.

The decline extends the ongoing retreat in mRNA-concept stocks and broader biotech sector weakness. Previously catalyzed by Merck and Moderna's positive Phase 3 clinical results for their personalized mRNA cancer vaccine, EVEREST MED had rallied as much as 55% from August 20. Recent sessions have seen sustained profit-taking as earlier gains are unwound. Within the Biotechnology sector, peers were broadly under pressure, with AKESO down 4.67%, BEONE MEDICINES down 4.81%, 3SBIO down 4.36%, CANSINOBIO down 4.03%, and INNOVENT BIO down 3.72%.

On the fundamental side, EVEREST MED reported first-half revenue of RMB 1.148 billion, up 157% year-over-year, achieving a turnaround to profitability. Core product TARPEYO saw sales growth of 94%. However, analysts have flagged risks including intensifying competition for TARPEYO and supply constraints for Xerava, while trimming revenue forecasts by 15%-18%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1122897904?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-31 10:09","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1122897904","market":"us","top_or_hot":-1,"title":"Movement Alert｜EVEREST MED Falls 5.19% in Regular Trading, mRNA Concept Pullback and Biotech Sector Weakness Weigh on Shares","media":"Market Focus","content":"<p><p>On August 31, EVEREST MED fell 5.19% in regular trading, trading at HK$33.0/share, with turnover of HK$108 million.</p><p>The decline extends the ongoing retreat in mRNA-concept stocks and broader biotech sector weakness. Previously catalyzed by Merck and Moderna's positive Phase 3 clinical results for their personalized mRNA cancer vaccine, EVEREST MED had rallied as much as 55% from August 20. Recent sessions have seen sustained profit-taking as earlier gains are unwound. Within the Biotechnology sector, peers were broadly under pressure, with AKESO down 4.67%, BEONE MEDICINES down 4.81%, 3SBIO down 4.36%, CANSINOBIO down 4.03%, and INNOVENT BIO down 3.72%.</p><p>On the fundamental side, EVEREST MED reported first-half revenue of RMB 1.148 billion, up 157% year-over-year, achieving a turnaround to profitability. Core product TARPEYO saw sales growth of 94%. However, analysts have flagged risks including intensifying competition for TARPEYO and supply constraints for Xerava, while trimming revenue forecasts by 15%-18%.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜EVEREST MED Falls 5.19% in Regular Trading, mRNA Concept Pullback and Biotech Sector Weakness Weigh on Shares</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜EVEREST MED Falls 5.19% in Regular Trading, mRNA Concept Pullback and Biotech Sector Weakness Weigh on Shares\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-08-31 10:09</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On August 31, EVEREST MED fell 5.19% in regular trading, trading at HK$33.0/share, with turnover of HK$108 million.</p><p>The decline extends the ongoing retreat in mRNA-concept stocks and broader biotech sector weakness. Previously catalyzed by Merck and Moderna's positive Phase 3 clinical results for their personalized mRNA cancer vaccine, EVEREST MED had rallied as much as 55% from August 20. Recent sessions have seen sustained profit-taking as earlier gains are unwound. Within the Biotechnology sector, peers were broadly under pressure, with AKESO down 4.67%, BEONE MEDICINES down 4.81%, 3SBIO down 4.36%, CANSINOBIO down 4.03%, and INNOVENT BIO down 3.72%.</p><p>On the fundamental side, EVEREST MED reported first-half revenue of RMB 1.148 billion, up 157% year-over-year, achieving a turnaround to profitability. Core product TARPEYO saw sales growth of 94%. However, analysts have flagged risks including intensifying competition for TARPEYO and supply constraints for Xerava, while trimming revenue forecasts by 15%-18%.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01952","symbol_name":"云顶新耀","start_time":0,"source_url":"","article_id":"1122897904","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1122897904","pubTimestamp":1788142185,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On August 31, EVEREST MED fell 5.19% in regular trading, trading at HK$33.0/share, with turnover of HK$108 million.The decline extends the ongoing retreat in mRNA-concept stocks and broader biotech...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01952":"云顶新耀"},"translate_title":"走势提醒|珠穆朗玛峰常规交易下跌5.19%，mRNA概念回调和生物技术板块疲软拖累股价","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01952":1},"content_text":"On August 31, EVEREST MED fell 5.19% in regular trading, trading at HK$33.0/share, with turnover of HK$108 million.The decline extends the ongoing retreat in mRNA-concept stocks and broader biotech sector weakness. Previously catalyzed by Merck and Moderna's positive Phase 3 clinical results for their personalized mRNA cancer vaccine, EVEREST MED had rallied as much as 55% from August 20. Recent sessions have seen sustained profit-taking as earlier gains are unwound. Within the Biotechnology sector, peers were broadly under pressure, with AKESO down 4.67%, BEONE MEDICINES down 4.81%, 3SBIO down 4.36%, CANSINOBIO down 4.03%, and INNOVENT BIO down 3.72%.On the fundamental side, EVEREST MED reported first-half revenue of RMB 1.148 billion, up 157% year-over-year, achieving a turnaround to profitability. Core product TARPEYO saw sales growth of 94%. However, analysts have flagged risks including intensifying competition for TARPEYO and supply constraints for Xerava, while trimming revenue forecasts by 15%-18%.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.49.0","shortVersion":"4.49.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1122897904","isCrawlerRequest":true}